NLY01 Phase 2

The research record

This is the project's file for this landmark, as written and checked. Sources are listed at the end; anything not yet confirmed is marked "Not yet verified".

Who

Neuraly, the company developing the drug; the mouse work behind it came from Johns Hopkins and Seulki Lee's group (landmark 53). The drug was designed to reach the brain and to block microglia (the brain's immune cells) from switching astrocytes into a harmful state.

What happened

In mice, NLY01 protected dopamine neurons by stopping microglia from turning astrocytes toxic (landmark 53). That gave the GLP-1 idea (landmark 20) an inflammation explanation as well as a metabolic one.

• Design. Phase 2, placebo-controlled (NCT04154072). 255 people with early Parkinson's at 60 sites in the US and Canada, randomised to weekly injections of NLY01 2.5 mg or 5.0 mg, or placebo, for 36 weeks. The registry shows the trial started on 27 Feb 2020 and completed on 14 Feb 2023, with no results posted.
• Result (27 Mar 2023, company release). The change from baseline in MDS-UPDRS Parts II + III combined did not reach statistical significance versus placebo. The drug was reported safe and well tolerated.
• Post hoc subgroup. In people under 60 (37% of the trial, 95 people) the company reported a drop of about 5 points at 36 weeks (p<0.01). Because this was looked at after the main result, it is a hint only and would need its own trial.

Why it moved us toward a cure

It tested whether blocking the microglia-to-astrocyte route, a mechanism with strong mouse data, helps people. The answer so far is no, in 36 weeks, at these doses. That narrows the inflammation-plus-GLP-1 idea, and fits the broader pattern of exenatide's Phase 3.

Outcome

Dead end for NLY01 in this trial. The link between inflammation and Parkinson's is not refuted: 36 weeks is short, and the lack of a peer-reviewed paper means the details cannot be checked. The younger-patient signal was not followed by a confirmatory trial in the sources read.

Sources

• Neuraly topline release, 27 Mar 2023 (Business Wire) (company statement; page blocked automated reading, content seen only via search summaries, which agree with each other)
• Neuraly, enrolment complete, Apr 2022
• Yun et al., Nat Med 2018;24:931, DOI 10.1038/s41591-018-0051-5 · ClinicalTrials.gov NCT04154072
• Not yet verified: the release text itself, including the 255, 60-site and under-60 figures; any peer-reviewed publication or conference data (none found in Europe PMC); the company's current status; which of the two doses drove the subgroup result; why no follow-up trial.